FDA lagging on nanotechnology

Share this article:
Former FDA deputy commissioner for policy Michael Taylor says the agency lacks the legal authority and financial and staff resources it needs to properly regulate food, drugs, medical devices, dietary supplements, and cosmetics containing nanotechnology materials.

“The pressures of expanding regulatory responsibilities and the increasing cost of doing business, coupled with the failure of Congress and successive administrations to adequately fund even FDA's base operations, are a real threat to FDA's ability to effectively oversee nanotechnology,” Taylor wrote in a Robert Wood Johnson Foundation report.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.